TickerTalks
Browse all tickers →
TickerTalks›$RXRX
RXRXRX

Recursion Pharmaceuticals, Inc.

$RXRX·$1.6B·Biotechnology·Healthcare
$2.94-2.5%YTD-29.4%1Y-46.6%
Mentions · last 7 days
2026-07-11: 70 posts2026-07-12: 164 posts2026-07-13: 279 posts2026-07-14: 183 posts2026-07-15: 261 posts2026-07-16: 227 posts2026-07-17: 179 posts1,378+29%
Price updated 4h ago·X counts updated 4h ago
RXRXRX
$RXRXRecursion Pharmaceuticals, Inc.
$2.95-2.48%1.4k posts+29%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $RXRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

AI-biotech at $3.31 with -22% FCF yield — the story is real but the operating economics haven't converged.

Recursion Pharmaceuticals is the AI-plus-lab-automation drug-discovery platform whose 2026 tape has been penalized at -21% YTD despite genuine platform momentum. The stock is coiled at 12% of the 52-week range with real cash burn and a narrative-driven bull thesis.

  • The core business is pre-revenue and cash-consumptive: Q1 2026 revenue fell 56% YoY to $6.5M (specific comp effect), gross margin at -34%, operating margin at -1,986% — this is not a business you value on trailing multiples, and FCF yield of -22% shows the platform is still in build-mode.
  • The AI-biotech narrative has real institutional interest: CFO Ben Taylor joined Opto Sessions podcast discussing how Recursion uses AI, lab automation, biological data, and machine learning — the platform pitch is legitimate, and community accumulation is anchoring around the ABCL / RXRX 'AI biotech basket.'
  • Insider action is heavy: 11 insider events in the quarter with real grants and equity alignment — no scale open-market distribution near current levels, so the setup is quiet accumulation into the August 4 print with the technical low at $3.

The August 4 Q2 earnings are the near-term arbiter — cash-runway commentary (need clear path to 24+ months), any specific pipeline milestones or partnership commentary from Bayer / Roche / NVIDIA extend the coiling setup. Continued negative operating margin without a partnership catalyst confirms the too-early framing and drops the tape below $3.

Agrees with X sentimentX is bullish AI-biotech, cites CFO Ben Taylor on Opto Sessions podcast, community accumulation with ABCL as 'a massive gift dip,' and long-term hold framing. Mechanics support the too-early + coiling read: pre-revenue with -22% FCF yield is real capital-consumption profile, but 11 insider events with equity alignment and the specific AI-lab-automation platform pitch are legitimate. The August 4 print has to affirm cash-runway and pipeline milestones.

What to watch: The August 4 Q2 earnings. Watch cash-runway commentary (need clear path to 24+ months), pipeline milestone updates, and Bayer/Roche/NVIDIA partnership commentary. Continued negative operating margin without a partnership catalyst confirms too-early framing sub-$3; milestone or partnership extends the coil.

On the calendar: 2026-08-04 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-07-15

Recursion Pharmaceuticals chatter is bullish AI-biotech. RXRX CFO Ben Taylor joined Opto Sessions podcast discussing how Recursion uses AI, lab automation, biological data and machine learning. Community members are accumulating RXRX alongside ABCL as 'a massive gift' dip. Bulls set RXRX as a long-term hold. Community broadly long.

Read the AI verdict + X sentiment for $RXRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Uses AI and high-throughput biology to build drug discovery pipelines, combining biological maps with computational design.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RXRX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $RXRX

Partial — Uses AI and high-throughput biology to build drug discovery pipelines, combining biological maps with computational design; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-47.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-8.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-22.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
22.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-54.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-34.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 6, 2026$-0.22$-0.30+26.7%
Q4 2025Feb 25, 2026$-0.21$-0.28+25.0%
Q3 2025Nov 5, 2025$-0.36$-0.38+5.3%
Q2 2025Aug 5, 2025$-0.41$-0.35-17.1%
Next earningsTue, Aug 4·consensus EPS $-0.25

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$6.5M-56.1%-93.0%-1986%$-0.22$-81.4M
Q4 FY25$35.5M+687.8%24.4%-305%$-0.21$-47.3M
Q3 FY25$5.2M-80.2%-472%-3328%$-0.36$-117.6M
Q2 FY25$19.1M+32.6%-5.5%-923%$-0.41$-79.6M

Forward consensus

4-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$59.6M$22.5M – $79.2M-$0.93-$1.15 – -$0.786
FY27$85.5M$63.5M – $107.5M-$0.93-$1.18 – -$0.806
FY28$153.7M$153.7M – $153.7M-$0.76-$1.12 – -$0.273
FY29$247.5M$125.8M – $337.2M-$0.94-$1.38 – -$0.342

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.4%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-11.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-26.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 348.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today5.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.995-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 7Blake BorgesonDirector40.0K sh$159KSellJun 18Namandje BumpusDirector4.0K sh$13KSellJun 5Christopher GibsonDirector40.0K sh$145KSellJun 5Najat KhanCEO23.6K sh$84KSellJun 3Namandje BumpusDirector4.4K sh$16KSellJun 2Blake BorgesonDirector30.0K sh$110KSellMay 22Christopher GibsonDirector40.0K sh$123KSellMay 7Christopher GibsonDirector40.0K sh$135KSellMay 5Blake BorgesonDirector30.0K sh$106KSellApr 22Christopher GibsonDirector40.0K sh$144K
1–10 of 20
+ 42 other (15 awards · 15 inkinds · 10 conversions · 2 gifts) in window

See when $RXRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Delaware 001-40323 46-4099738 disclosed voting results from its annual or special meeting. hange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. Recursion...

8-KPress release / Reg FDMay 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

RXRX reported first quarter March 31, 2026. A copy of the press rel financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

8-KOfficer or director changeApr 308-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

RXRX disclosed a personnel change (8-K Item 5.02, dated 2026-04-30). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KOfficer or director changeMar 258-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

RXRX disclosed a personnel change (8-K Item 5.02, dated 2026-03-25). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

424B5Prospectus supplement (offering)Feb 25424B5
8-KPress release / Reg FDFeb 258-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 11 other (5 13Gs · 2 proxys · 1 10-Q · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Todayzacks.com·3d ago2 Beaten-Down Stocks That Still Aren't Worth Buyingfool.com·6d agoHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Marketzacks.com·9d ago3 Cancer Stocks to Watch as Oncology Innovation Accelerateszacks.com·10d agoCathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com·13d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$ALLO
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport